AzTrials
AzTrials

CancerPhase 2RESTNCT01334983

Rapid Easy Strength Training (REST) to Improve Function in Late Stage Cancer

A Phase 2 study testing REST in people with Cancer, run by Mayo Clinic at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether a gentle physical conditioning program comprised of isotonic resistive strengthening and pedometer-directed walking can improve the physical functioning and fatigue of patients with late stage lung or colon cancer. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer
What is being tested?
REST
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
1 siteUnited States
Study dates
Jun 2010to Nov 2010
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of Stage III or IV NSCLC or extensive stage SCLC, or Stage IV colon cancer
  • fluency in the English language
  • Intact cognitive status (Folstein mini-mental score > 25).

Who cannot join

  • Pain numeric rating scale (NRS) scores > 7/10,
  • Fatigue NRS score > 8/10,
  • paralysis of > 2 limbs (< antigravity strength in all major muscle groups),
  • Severe cerebellar ataxia,
  • Chronic (> 1 year) non-cancer pain either >5/10 or causing the patient to apply for or receive disability payments.
  • Severe medical or psychiatric co-morbidities such as major depression or unstable angina

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Mayo Clinic

    Rochester, Minnesota, 55905

Other trials in United States

About this study

Official title: Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer

The purpose of this study is to determine whether a gentle physical conditioning program comprised of isotonic resistive strengthening and pedometer-directed walking can improve the physical functioning and fatigue of patients with late stage lung or colon cancer.

Read the detailed description
  1. SPECIFIC AIMS

The results of this prospective pilot cohort study will be used to power and inform the design of a randomized controlled trial. Its specific aims are:

  1. To characterize the receptivity of patients with late stage lung or colon cancer to perform an individualized fitness program to prevent deconditioning and functional decline.
  2. To estimate the adherence of patients with LSC (LSC) to an individualized fitness program.
  3. To estimate the degree to which symptoms, e.g. fatigue and pain, associate with adherence to an individualized fitness program.
  4. To estimate improvements in functional status associated with performance of an individualized fitness program among patients with LSC.
  5. BACKGROUND AND SIGNIFICANCE Most people with LSC function poorly at diagnosis, deteriorate steadily over a period of months to years, and become dependent prior to death. Their disablement exacts staggering costs in quality of life (QoL), caregiver burden, and health care expenses. Oncologic clinicians, as a result of their training and focus on the treatment of cancer, often neither systematically detect nor treat the function and symptom problems that cause disablement. As a consequence rehabilitation therapies, even those with well documented evidence of benefit, tend to be under-utilized and provided too late to be maximally effective. The public health burden of this issue is likely to only worsen given the improving survival of patients with LSC and the increasing age and medical complexity of those being treated.
  6. STUDY DESIGN AND METHODS Design A randomized controlled trial. Duration Following enrollment, study participants will remain on the study for 2.5 months after instruction in their individualized REST program. REST titration and tailoring for participant specific barriers will occur over the telephone for the 2 week "initiation phase" after initial REST instruction. Thereafter, patients will perform their REST independently at home during the 8 week "training phase" with "as needed" telephone-based guidance from a PT. We therefore anticipate that the study will continue for a total of 6 months; 3 months to recruit 68 patients and an additional 2.5 months for all participants to complete initiation and training phases of the protocol.

Subject Enrollment Identification of participants. A sample of 68 patients with Stage III or IV NSCLC or Extensive stage SCLC, or Stage IV colon cancer will be identified.

Dr. Cheville will contact eligible patients by telephone after they receive a mailing describing the study and permitting them to opt out by returning a postage-paid postcard. A 'fold over' postcard will be sent so as to maintain the patient's privacy regarding lung or colon cancer diagnosis. Dr. Cheville's efforts to contact eligible patients will continue until 5 attempts have been made on different week days and times of day. Eligibility and inclusion and exclusion criteria will be assessed. If the patient is eligible, the study will be described in detail and verbal consent will be obtained from those desiring to participate. An informed consent form will be mailed to each patient willing to participate in the study to ensure that they have adequate opportunity to review the document. Informed consent will be obtained by Dr. Cheville when the patient comes to the Mayo Clinic for study enrollment. All questions will be answered prior obtaining informed consent.

Eligibility. Eligible subjects must have a diagnosis of Stage III or IV NSCLC or extensive stage SCLC, or Stage IV colon cancer and be receiving a chemotherapeutic regimen that requires visits to the Mayo Clinic Department of Medical Oncology < every 4 weeks for the first 6 weeks following enrollment or undergoing monitoring visits at comparable intervals. Pathological confirmation is not required if the oncology provider specializing in lung cancer has a high level of certainty regarding the diagnosis. Entry criteria will not consider number or location of metastases or prior treatment. The participants will be required to be fluent in the English language and have intact cognitive status (Folstein mini-mental score > 25).

Recruitment. Approximately 50 new lung cancer cases are diagnosed each month at the Mayo Clinic. Of these, about 70% are initially diagnosed with Stage III or Stage IV NSCLC or Extensive Stage SCLC and 60% elect to receive their cancer-related care at Mayo. Recruitment rates in our previous work in this population have been high. The proposed intervention entails greater patient commitment and we anticipate a recruitment rate of 50%. We will target patients meeting the study criteria who are undergoing ongoing treatment at the MCCC as well as those who are newly diagnosed. We anticipate a recruitment rate of 10 patients per month and that recruitment will continue for 3 months. We have not previously recruited patients with colon cancer, but anticipate recruitment of 10 patients per month based on the experience of other researchers.

Randomization. Patients will be block randomized to the REST intervention or wait-list control. Stratified randomization will not be used.

Intervention Overview. The intervention is provision of an individualized, 2-part, 3-tiered REST program which will include the exercises listed in Table 1 to all participants randomly assigned to the intervention arm. In addition, participants will receive a step pedometer and will be encouraged to remain as active as possible during the study period based on objective feedback from their pedometer readings. A PT specialized in cancer rehabilitation will instruct participants in REST and will adapt the program to accommodate for symptoms, co-morbidities, or other issues that may impede a participant's ability to perform the REST program. The PT will follow up with each participant by telephone at 1- and 2-weeks following REST instruction to encourage participants and to problem solve regarding any barriers which may be impeding their performance of REST. After the 2-week initiation phase, participants will perform REST independently during an 8 week training phase but will be encouraged to contact the PT with any questions or difficulty. Patient reported outcome (PROs) measures will be collected at baseline prior to REST instruction and after completion of the 2-month training phase, as outlined below.

Baseline assessment and REST instruction. Patients will be examined and instructed in their REST programs on a day when they will be visiting the Mayo clinic either for treatment or evaluation. REST will not be feasible if it adds to patients' already significant travel demands. The PI will obtain a functional history and perform a routine physical examination on all patients to ensure that they may safely participate and to identify impairments or physical vulnerabilities that will require individualizing their REST program. A tailored REST fitness program will be developed for each patient by a PT specialized in cancer rehabilitation. Patients will be provided with upper and lower extremity REST routines (each requiring 7 minutes) designed to maintain core and appendicular strength with minimal burden. The REST lower extremity routine will include 6 exercises and will target the hip flexors, hip abductors, hip extensors, knee extensors, knee flexors, shoulder stabilizers, and back extensors. The REST upper extremity routine will include 5 exercises and will target the elbow extensors, elbow flexors, shoulder stabilizers, shoulder flexors, and abdominal muscles. Each routine can be performed at 1 of 3 intensity levels depending on how participants feel on a given day. Each of the routines is performed twice per week for a maximum total of 28 minutes of resistive strengthening per week. The standard REST lower extremity program is performed in a standing position; however the program can be adapted for seated performance. Note that the REST program can also be individualized to accommodate impairments such as degenerative arthritis, back pain and osseous instability.

Subjects will also be dispensed a pedometer and encouraged to wear it daily for the first 2 weeks of their study enrollment in order to establish an average baseline number of steps per day. Thereafter they will be instructed to wear the pedometer 3 times per week and to chart the number of steps taken between waking and retiring to bed and encouraged to 'make up' for days/weeks when fewer steps are taken due to increased symptom burden, post-chemotherapy fatigue, or other contingency.

Subjects will be provided with laminated cards illustrating their REST program to encourage their adherence. They will also receive a ring bound monthly calendar with their REST program illustrated on the top and a calendar on the bottom with designated boxes for number of pedometer recorded steps per day and to indicate which (if any) tier of the REST program they completed on a given day. Calendars will be submitted for analysis at the end of the 2 month study period. Modified laminated cards and calendar pages will be provided if changes in their health status require alterations of their REST program.

Initiation phase. Participants will be encouraged to perform their upper extremity and lower extremity REST programs twice per week. After the first week, they will follow up with the study PT by telephone to address any questions they may have and to address any difficulties with REST. The PT may adjust their REST program if it proves uncomfortable or overly fatiguing. Participants will continue to perform the REST program with any modifications for the second week after training. They will again follow up with the study PT by telephone at the end of the second week to address any issues. Dr. Cheville will serve as resource for the study PT during the initiation phase in case he/she has any questions regarding symptom control or the safety of REST.

Training phase. Following the initiation phase the participants will continue to perform their REST programs 4 times per week (2 upper and 2 lower extremity) for 8 weeks. While no follow up telephone calls will be scheduled with the study PT, participants will be encouraged to contact the PT with any questions or difficulties. The PT will consult Dr. Cheville on an as needed basis.

Data Collection Patient-Reported Outcome (PRO) Measures. Baseline PROs will be collected after subjects sign informed consent, following randomization and, for intervention group members, before the PTs instruct them in the REST exercises. Week 10 PROs will be mailed to the patients with a postage paid return envelope. Participants who do not respond in the first week will be sent a second mailing. Subjects will receive $25.00 compensation for completing each set of PROs, for a total of $50.00.

Ambulatory Post Acute Care Basic Mobility and Daily Activity Short Forms FACIT-F Outcome Expectations for Exercise Self Efficacy for Exercise North Central Cancer Trials Group Patient Quality of Life-Linear Analogue Self Assessment (LASA) Scale. The LASA Scale is a single item measurement of global quality of life rating on a numerical rating scale from 0 to 10 with well established validity data in cancer populations.38 Other Treatments. Oncological care will be not affected by this study: subjects will continue to make their routine clinic visits and receive oncological cares as usual. Analgesic medications will be permitted (and assessed), to adjust for co-intervention differences between groups in the analyses.

STATISTICAL ANALYSIS Descriptive statistics will be calculated for participants' demographic and lung cancer-related characteristics, as well as their function- and symptom-related PROs. Descriptive statistics will also be calculated for the data collected by the study PT regarding the frequency of specific problems (e.g. shoulder pain with REST) encountered during the initiation phase, as well as the number of calls per participant during the training phase, time per call, and reasons for these calls.

Data collected from patients' calendar records of REST adherence and steps per day will be described in terms of proportions and means, respectively. An arbitrary threshold of 75% will be used to distinguish participants who did and did not adhere to the recommended 4 sessions per week. Participants who did not perform their REST program 4 times per week for at least 6 of the 8 weeks during the training phase will be considered non-adherent. Exploratory analyses of significant differences between participants that did and did not adhere will be performed with nonparametric testing.

The normality of the PROs will be assessed by testing of skew and kurtosis. Nonparametric statistical tests will be used to evaluate PROs that are not normally distributed. Student's paired T-test will be used to estimate the effect of the intervention on primary and secondary outcomes. Additionally, the Wilcoxon rank sum test will be used to compare the degree of change in these scores between patients randomized to the intervention group who did and did not comply with REST. The magnitude and directions of the relationships between change in mean steps per day during the training interval (calculated as mean from week 10 minus mean from baseline) and changes in PRO scores will be assessed with Pearson correlation coefficients. Given the pilot nature of this work, adjustments will not be made for multiple comparisons.

Conditions
Cancer
Being tested
REST
Keywords
cancer, function, fatigue, late stage, metastases, quality of life, functional decline in cancer
Medical subject headings
Neoplasms, Fatigue, Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RESTBehavioural

    Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.

Study groups in NCT01334983
Study groupRoleWhat they receive
RESTExperimentalParticipants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
Receives: Behavioral: REST
Wait list controlNo interventionParticipants instructed in REST after completing week 8 outcome measures

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ambulatory Post Acute Care Basic Mobility Short Form

    Patient reported outcome with 18 items assessed functionality in basic mobility. Response option for all items is a 4 level Likert scale

    Measured: 8 weeks

Secondary outcomes (3)
  1. Ambulatory Post Acute Care Short Form Daily Activities

    Patient reported outcome with 15 items assessing functionality with respect to the performance of activities of daily living.

    Measured: 8 weeks

  2. Linear Analoge Self Assessment of Quality of Life

    7 item patient reported outcome assessing over-all quality of life and quality of life domains, e.g. mental, social, etc.

    Measured: 8 weeks

  3. FACIT-F

    Patient reported outcome assessing overall quality of life among patients with cancer and fatigue

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Apr 2011 (estimated)
  2. Study startJun 2010
  3. Primary completionNov 2010
  4. Study completionNov 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01334983
Sponsor's protocol ID
09-007108
Acronym
REST
Status last verified
Apr 2015
First submitted
12 Apr 2011
Last updated
18 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing REST in people with Cancer, run by Mayo Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ambulatory Post Acute Care Basic Mobility Short Form (time frame: 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
REST Clinical Trial NCT01334983 | AzTrials